CHICAGO, June 29, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: WellPoint (NYSE: WLP), Amerigroup (NYSE: AGP), WellCare Health Plans (NYSE: WCG), Magellan Health Services (Nasdaq: MGLN) and Coventry Health Care (NYSE: CVH).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
HMO Stocks for Healthy Profits
An industry group with surprisingly steady profits from several players is that of HMOs. Big cap names like WellPoint (NYSE: WLP) have experienced frequent periods of upward earnings estimate revisions in the past year and watched their share prices surge 40% to 80%.
12th Out of 265 Industries
There are 18 companies in the Zacks HMO Industry group and, collectively, they have such strong earnings growth that they take the number 12 spot among 264 other groups. On Monday, there were five companies with the coveted Zacks #1 Rank (strong buy) including Humana and WellPoint, which just got bumped down to a #3 Rank (hold) today.
A handful of mid cap and small cap names in this space have also done well and may still be worth watching. They are listed below with market cap, forward P/E multiple, and performance.
Amerigroup (NYSE: AGP): $3.3 billion, 15 P/E; stock has consistently been a Zacks #1 or #2 Rank since August 2010 and it has doubled from $35 to $70.
WellCare Health Plans (NYSE: WCG): $2.1 billion, 13 P/E; stock has doubled from $25 to $50 since last July while earning a Zacks #2 or #3 Rank, with occasional #1 showings.
Magellan Health Services (Nasdaq: MGLN): $1.7 billion, 14.5 P/E; stock has moved from $35 to just over $50 in past year and recently began earning Zacks #1 and #2 Ranks since April.
Coventry Health Care (NYSE: CVH): $5 billion, P/E of 12; stock has consistently earned a #2 or #3 Zacks Rank, with occasional #1 showings in past year, and went from $17 to $35.
Part of Healthy Portfolio?
Based on the across-the-board outperformance of this group, it seems a solid HMO or two could find a welcome place in one's investments. Investors may want to consider a reliable large cap name and a higher-growth mid or small cap entrant.
The key to stock selection may rest with a combination of timing and successful identification of earnings growth and momentum. To get a quick and easy read on those profit metrics, you have to look no further than the Zacks Rank every day.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.